What is the PHQ-2 test?

The PHQ-2 inquires about the frequency of depressed mood and anhedonia over the past two weeks. The PHQ-2 includes the first two items of the PHQ-9. The purpose of the PHQ-2 is to screen for depression in a “first-step” approach.

What do PHQ scores mean?

Scores represent: 0-5 = mild 6-10 = moderate 11-15 = moderately severe. 16-20 = severe depression. • GAD-7 Anxiety Severity. This is calculated by assigning scores of 0, 1, 2, and 3, to the response categories of “not at all,”

What is a positive PHQ-9?

When screening for depression the Patient Health Questionnaire (PHQ-2) can be used first (it has a 97% sensitivity and a 67% specificity). If this is positive, the PHQ-9 can then be used, which has 61% sensitivity and 94% specificity in adults.

What questions are on the PHQ-9?

PHQ9: In the last 2 weeks… o Have you had little interest or pleasure in doing things? o Have you been feeling down, depressed or hopeless? o Have you had trouble falling or staying asleep or sleeping too much? o Have you been feeling tired or have little energy? o Have you had a poor appetite or have been overeating? …

What is the purpose of the PHQ-2?

The purpose of the PHQ-2 is to provide a brief, initial screening for major depression. Adapted from the PHQ-9, this tool has been used as a first step in depression screening to identify individuals who require additional evaluation. The PHQ-2 covers only major depressive disorder.

What is a normal GAD-7 score?

A score of 10 or greater on the GAD-7 represents a reasonable cut point for identifying cases of GAD. Cut points of 5, 10, and 15 might be interpreted as representing mild, moderate, and severe levels of anxiety on the GAD-7, similar to levels of depression on the PHQ-9.

What is considered a positive PHQ 2?

As an example, on Table 2▶, a PHQ-2 score of 2 or higher has a sensitivity of 0.86, meaning that 86% of those with a major depression will be found to be positive on the PHQ-2 screening test.

What is the purpose of PHQ-9?

Its purpose is not to establish final diagnosis or to monitor depression severity, but rather to screen for depression. Patients who screen positive should be further evaluated with the PHQ-9 to determine whether they meet criteria for a depressive disorder.

When should the PHQ-9 Be Used?

The PHQ-9 is a simple, nine question form used to screen depression and monitor changes in signs/symptoms of depression. The patient’s PHQ-9 score should be recorded at the beginning of a visit, like blood pressure or other vitals.

What is the difference between PHQ-9 and PHQ A?

Measuring sensitivity and specificity, a second meta-analysis found the PHQ-9 to have a sensitivity of 0.85 and specificity of 0.89 at a cutoff of 11. In comparison to the PHQ-9, the PHQ-A identified a sensitivity of 0.73 and a specificity of 0.94 in adolescents with major depressive disorder (Johnson et al., 2002).

What do you need to know about the PHQ-2?

The PHQ-2 inquires about the frequency of depressed mood and anhedonia over the past two weeks. The PHQ-2 includes the first two items of the PHQ-9. n The purpose of the PHQ-2 is not to establish final a diagnosis or to monitor depression severity, but rather to screen for depression in a “first step” approach.

How to use the Patient Health Questionnaire-9 ( PHQ-9 )?

The Patient Health Questionnaire-9 (PHQ-9) Instructions Instructions: To further evaluate patients with PHQ-2 scores of 3 or more, administer or have them complete the questionnaire on the next page. USE OF THE PHQ-9 TO MAKE A TENTATIVE DEPRESSION DIAGNOSIS

How to use the PHQ-2 to diagnose depression?

Instructions: To further evaluate patients with PHQ-2 scores of 3 or more, administer or have them complete the questionnaire on the next page. USE OF THE PHQ-9 TO MAKE A TENTATIVE DEPRESSION DIAGNOSIS The clinician should rule out physical causes of depression, normal bereavement, and a history of a manic/hypomanic epi – sode. Step 1:

Who is the inventor of the PHQ-2 questionnaire?

The PHQ-2 has been validated in 3 studies in which it showed wide variability in sensitivity (Gilbody, Richards, Brealey, and Hweitt, 2007). Developed by Drs. R.L. Spitzer, J.B.W. Williams, K. Kroenke and colleagues, with an educational grant from Pfizer, Inc. No permission required to reproduce, translate, display or distribute.